DiscGenics Overview

  • Founded
  • 2007
Founded
  • Status
  • Private
  • Employees
  • 32
Employees
  • Latest Deal Type
  • Series C1
  • Latest Deal Amount
  • $50M
Latest Deal Amount
  • Investors
  • 6

DiscGenics General Information

Description

Operator of a clinical-stage biopharmaceutical company intended to develop regenerative cell-based therapies for diseases of the spine. The company's services include developing an allogeneic cell therapy which is a homologous, injectable cell therapy that utilizes biomedically engineered progenitor cells derived from intervertebral disc tissue known as discogenic cells to treat diseases of the disc, enabling patients to have access to a non-surgical and regenerative alternative that alleviates pain and restores function.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 5940 West Harold Gatty Drive
  • Salt Lake City, UT 84116
  • United States
+1 (801) 000-0000

DiscGenics Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

DiscGenics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C1) 25-Aug-2020 $50M 0000 00000 Completed Clinical Trials - Phase 2
4. Debt - PPP 15-Apr-2020 0000 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series B) 31-Aug-2017 0000 0000 0000 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A2) 30-Nov-2013 $3M $7M Completed Pre-Clinical Trials
1. Early Stage VC (Series A1) 21-Oct-2012 $4M $4M Completed Startup
To view DiscGenics’s complete valuation and funding history, request access »

DiscGenics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-1 0,000,000 00.000000 00.00 000.00 000.00 00 000.00 00.000
Series C 0,000,000 00.000000 00.00 000.00 000.00 00 000.00 00.000
Nonvoting Series C 0 00.000000 00.00 000.00 000.00 00 000.00 00
Nonvoting Series B 53,387 $0.001000 $0.24 $4.03 $4.03 1x $4.03 0%
Series B 3,921,454 $0.001000 $0.24 $4.03 $4.03 1x $4.03 33.17%
To view DiscGenics’s complete cap table history, request access »

DiscGenics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a clinical-stage biopharmaceutical company intended to develop regenerative cell-based therapies for disease
Drug Discovery
Salt Lake City, UT
32 As of 2021
0000
0000 0000-00-00
00000000000 0000

00000000

n reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occae
0000000000000
Melbourne, Australia
00 As of 0000
00000
000000000 00000

00000000

d exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in rep
00000000000 0000000
Melville, NY
0 As of 0000
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DiscGenics Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mesoblast Corporation Melbourne, Australia 00 00000 000000000 00000
00000000000000 000 Corporation Melville, NY 0 00000000
You’re viewing 2 of 2 competitors. Get the full list »

DiscGenics Executive Team (9)

Name Title Board Seat Contact Info
Flagg Flanagan Co-Founder, Chief Executive Officer & Chairman
Jeffrey Poole Chief Financial Officer
Robert Wynalek Chief Operating & Commercialization Officer
Anthony Mangum Manager
Kevin Foley MD Co-Founder, Chief Medical Officer & Board Member
You’re viewing 5 of 9 executive team members. Get the full list »

DiscGenics Board Members (4)

Name Representing Role Since
Colin Novick Self Board Member 000 0000
Flagg Flanagan DiscGenics Co-Founder, Chief Executive Officer & Chairman 000 0000
Kevin Foley MD Self Co-Founder, Chief Medical Officer & Board Member 000 0000
Najeeb Thomas MD Self Board Member 000 0000
To view DiscGenics’s complete board members history, request access »

DiscGenics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DiscGenics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CareNet Corporation Minority 000 0000 000000 0
Ci:z Investment Venture Capital Minority 000 0000 000000 0
Eagle Fund SP1 Venture Capital Minority 000 0000 000000 0
Medical Incubator Japan Venture Capital Minority 000 0000 000000 0
Mitsubishi UFJ Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »